That's significant because the GI tract is the most common site of bleeding with DOACs, and this type of bleeding is the only ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, ...

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

The use of anticoagulants offers significant benefits. They are indicated for various uses depending on the specific anticoagulant used, including: These medications protect individuals at high ...

TAHO Pharmaceuticals is pleased to announce the successful completion of the pivotal trial for TAH3311, the first anticoagulant oral dissolving film (ODF). This trial was conducted following detailed ...

Glenmark Pharmaceuticals has launched Phytonadione injectable emulsion through its US arm, targeting anticoagulant markets.

Atrial fibrillation (AF) is a common heart condition that affects about one in three people at some point in their lives. It ...

Investigators believe that this new anticoagulant, named tecarfarin, will be associated with less therapeutic variability than warfarin because its structure precludes it from being metabolized by ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

The true incidence of thrombosis among people who received targeted therapy for breast cancer is significantly higher than ...

Risk for bleeding events is significantly affected by DOAC score in patients with atrial fibrillation who have received TAVR.

It further said that the single-dose ampules are both bioequivalent and therapeutically equivalent to the reference listed ...